GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of liver events and hepatocellular carcinoma in patients with type 2 diabetes compared with other glucose-lowering therapies.[1] Researchers analyzed a cohort of 16,000 U.S. Veterans Health Affairs patients with MASLD and diabetes who started treatment with GLP-1 agonists, compared with 16,000 patients taking DPP-4 inhibitors.[1] In noncirrhotic patients, GLP-1 agonists were associated with a lower risk of progression to cirrhosis and lower all-cause mortality compared to DPP-4 inhibitors.[1] In cirrhotic patients, which comprised approximately 10% of the population, there were no significant differences in the risk of cirrhosis complications or overall mortality.[1] These observational results suggest a small but significant improvement in clinical outcomes with the use of GLP-1 agonists in patients with MASLD and diabetes without cirrhosis.[1] Little is known about the clinical outcomes of GLP-1 agonists in patients with MASLD.[1]